UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
enzalutamide (723) 723
science & technology (499) 499
life sciences & biomedicine (494) 494
prostate cancer (451) 451
humans (346) 346
male (328) 328
oncology (286) 286
abiraterone (272) 272
phenylthiohydantoin - analogs & derivatives (252) 252
prostatic neoplasms, castration-resistant - drug therapy (209) 209
androgen receptor (168) 168
metastasis (161) 161
castration-resistant prostate cancer (151) 151
phenylthiohydantoin - therapeutic use (151) 151
cancer (134) 134
urology & nephrology (134) 134
androgens (124) 124
docetaxel (121) 121
prostatic neoplasms, castration-resistant - pathology (120) 120
abiraterone acetate (116) 116
antineoplastic agents - therapeutic use (112) 112
aged (108) 108
treatment outcome (105) 105
cabazitaxel (99) 99
chemotherapy (92) 92
care and treatment (89) 89
prostate (86) 86
middle aged (85) 85
phenylthiohydantoin - pharmacology (84) 84
animals (82) 82
receptors, androgen - metabolism (80) 80
castration (78) 78
cell line, tumor (71) 71
cancer therapies (70) 70
metastatic castration-resistant prostate cancer (69) 69
prostatic neoplasms - drug therapy (67) 67
drug resistance, neoplasm (65) 65
drug therapy (63) 63
analysis (62) 62
aged, 80 and over (61) 61
pharmacology & pharmacy (61) 61
prostatic neoplasms - pathology (54) 54
androgen antagonists - therapeutic use (53) 53
disease-free survival (53) 53
metastases (53) 53
research (53) 53
neoplasm metastasis (52) 52
prostatic neoplasms, castration-resistant - metabolism (50) 50
endocrinology & metabolism (49) 49
phenylthiohydantoin - administration & dosage (49) 49
urology (48) 48
patients (47) 47
prostatic neoplasms, castration-resistant - blood (47) 47
receptors, androgen - genetics (46) 46
development and progression (45) 45
medicine & public health (45) 45
clinical trials (44) 44
disease progression (44) 44
mice (44) 44
prostate-specific antigen - blood (44) 44
retrospective studies (43) 43
antineoplastic agents - pharmacology (42) 42
drug resistance (42) 42
prostatic neoplasms, castration-resistant - mortality (42) 42
antineoplastic combined chemotherapy protocols - therapeutic use (41) 41
cell proliferation - drug effects (41) 41
bicalutamide (40) 40
castration resistant prostate cancer (40) 40
cell biology (40) 40
review (40) 40
prognosis (39) 39
taxoids - therapeutic use (38) 38
androgen receptor antagonists - therapeutic use (37) 37
gene expression (36) 36
urologic and male genital diseases (36) 36
androstenes - therapeutic use (35) 35
signal transduction - drug effects (35) 35
antiandrogens (34) 34
apalutamide (34) 34
phenylthiohydantoin - adverse effects (33) 33
antigens (32) 32
radium-223 (32) 32
health aspects (31) 31
sipuleucel-t (31) 31
survival (31) 31
apoptosis (30) 30
testosterone (30) 30
drug resistance, neoplasm - drug effects (29) 29
hematology, oncology and palliative medicine (28) 28
tumors (28) 28
denosumab (27) 27
medical research (27) 27
prostatic neoplasms - metabolism (27) 27
xenograft model antitumor assays (27) 27
androgen deprivation therapy (26) 26
antineoplastic agents, hormonal - therapeutic use (26) 26
ar-v7 (26) 26
biochemistry & molecular biology (26) 26
prostate-specific antigen (26) 26
prostatic neoplasms, castration-resistant - genetics (26) 26
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (710) 710
German (20) 20
Russian (17) 17
French (13) 13
Czech (6) 6
Spanish (4) 4
Hungarian (3) 3
Japanese (3) 3
Chinese (2) 2
Portuguese (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Medicine Insights. Oncology, ISSN 1179-5549, 12/2016, Volume 2016, Issue Suppl. 1, pp. 1 - 9
Despite the introduction of novel therapies that maximally decrease androgen-receptor (AR) signaling activity, metastatic castration-resistant prostate cancer... 
Castration-resistant prostate cancer | Resistance | Enzalutamide | Abiraterone | Novel androgen-directed therapy
Journal Article
Annals of oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1508 - 1516
Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically... 
Castration-resistant prostate cancer | Biomarker | Enzalutamide | Abiraterone | Plasma DNA | Androgen receptor | Life Sciences & Biomedicine | Oncology | Science & Technology | Phenylthiohydantoin - adverse effects | Multivariate Analysis | Predictive Value of Tests | Prospective Studies | Circulating Tumor DNA - genetics | Phenylthiohydantoin - therapeutic use | Humans | Middle Aged | Male | Prostatic Neoplasms, Castration-Resistant - genetics | Patient Selection | Antineoplastic Agents, Hormonal - adverse effects | Time Factors | DNA Mutational Analysis | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Adult | Odds Ratio | Precision Medicine | Receptors, Androgen - blood | Androstenes - adverse effects | Prostatic Neoplasms, Castration-Resistant - blood | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Androstenes - therapeutic use | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Multiplex Polymerase Chain Reaction | Disease Progression | Phenylthiohydantoin - analogs & derivatives | Biomarkers, Tumor - blood | Disease-Free Survival | Receptors, Androgen - genetics | Aged | Biomarkers, Tumor - genetics | Prostatic Neoplasms, Castration-Resistant - mortality | Circulating Tumor DNA - blood | Mutation | Index Medicus | androgen receptor | abiraterone | Editor's Choice | castration-resistant prostate cancer | plasma DNA | biomarker | Original | enzalutamide
Journal Article
Journal Article
European urology, ISSN 0302-2838, 01/2015, Volume 67, Issue 1, pp. 53 - 60
Abstract Background Enzalutamide is a novel antiandrogen with proven efficacy in metastatic castration-resistant prostate cancer (mCRPC). Objective To evaluate... 
Urology | Castration-resistant prostate cancer | Primary resistance to enzalutamide | Androgen signaling inhibition | Bone metastasis | Bone tumor microenvironment | Adaptive feedback mechanism | Androgen receptor | Predictors of outcome | Enzalutamide | Tissue-based research | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Prospective Studies | Phenylthiohydantoin - therapeutic use | Humans | Middle Aged | Receptors, Androgen - metabolism | Retroviridae Proteins, Oncogenic - metabolism | Bone Neoplasms - secondary | Cytoplasm - metabolism | Drug Resistance, Neoplasm | Ki-67 Antigen - metabolism | Male | Antineoplastic Agents - therapeutic use | Receptors, Glucocorticoid - metabolism | Prostatic Neoplasms, Castration-Resistant - pathology | Bone Neoplasms - metabolism | Cell Nucleus - metabolism | Protein Isoforms - metabolism | Bone Marrow - metabolism | Aged, 80 and over | Adult | Bone Neoplasms - drug therapy | Testosterone - blood | Gene Dosage | Prostatic Neoplasms, Castration-Resistant - drug therapy | Prostatic Neoplasms, Castration-Resistant - metabolism | Bone Marrow Neoplasms - secondary | Phenylthiohydantoin - analogs & derivatives | Prostate-Specific Antigen - blood | Receptors, Androgen - genetics | Signal Transduction - drug effects | Bone Marrow Neoplasms - metabolism | Aged | Bone Marrow Neoplasms - drug therapy | Steroid 17-alpha-Hydroxylase - metabolism | Prostate cancer | Metastasis | Index Medicus | Bone marrow biopsy | Androgen | Antiandrogens
Journal Article
European urology, ISSN 0302-2838, 02/2014, Volume 65, Issue 2, pp. 467 - 479
Journal Article
European urology, ISSN 0302-2838, 05/2018, Volume 73, Issue 5, pp. 715 - 723
Journal Article
Current drug targets, ISSN 1389-4501, 2018, Volume 19, Issue 6, pp. 613 - 620
Understanding and targeting the mechanisms of resistance to enzalutamide in castration resistant prostate cancer. Background: Enzalutamide (MDV3100, XTANDI) is... 
Castration-resistant prostate cancer | Biomarker | Inhibitor | Enzalutamide | Drug resistance | Androgen receptor | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Androgens | Castration | Biomarkers | Pharmacology | Prostate cancer | Prostate | Chemical compounds | Cancer
Journal Article